Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.

ABSTRACT:

Background

Children with human immunodeficiency virus type 1 (HIV-1) infection have limited options for effective antiretroviral treatment (ART).

Methods

We conducted an open-label, randomized, noninferiority trial comparing three-drug ART based on the HIV integrase inhibitor dolutegravir with standard care (non-dolutegravir-based ART) in children and adolescents starting first- or second-line ART. The primary end point was the proportion of participants with virologic or clinical treatment failure by 96 weeks, as estimated by the Kaplan-Meier method. Safety was assessed.

Results

From September 2016 through June 2018, a total of 707 children and adolescents who weighed at least 14 kg were randomly assigned to receive dolutegravir-based ART (350 participants) or standa

SUBMITTER: Turkova A 

PROVIDER: S-EPMC7614690 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature